Please login to the form below

Not currently logged in
Email:
Password:

HEC

This page shows the latest HEC news and features for those working in and with pharma, biotech and healthcare.

Merck plans expanded filing for Emend this year

Merck plans expanded filing for Emend this year

The single-dose regimen is already approved for use in highly-emetogenic chemotherapy (HEC), but Merck says it will now file the results with regulators later this year to broaden

Latest news

  • Roche eases developing world Tamiflu access

    Sub licences for manufacture have been issued to Hetero in India, Shanghai Pharma and HEC in China, and a technology transfer issued to Aspen Pharmaceuticals in South Africa.

  • GSK files NDA in the US

    Patients who have undergone highly emetogenic chemotherapy (HEC) have a 90 per cent chance of experiencing CINV, which can last for up to five days. ... Phase III trial of the new drug, involving HEC patients, showed a patient response rate of 86 per

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics